光啟技術(002625.SZ):順德項目一期完成封頂 預計12月正式投產
格隆匯7月16日丨光啟技術(002625.SZ)公佈,公司的銀星基地已於近期完成產能擴建,產能提升為8000公斤,一定程度上滿足了公司部分日益增長的業務及訂單需求。
公司的順德產業基地項目(以下簡稱“順德項目”)作為公司的募投重點項目,計劃總投資14.9億元,是公司新一代超材料尖端裝備產品批量生產的創新型產業基地,共規劃分兩期建設,一期、二期建設各36個月。
7月14日,順德項目一期順利完成封頂,公司預計今年10月建成試產,12月正式投產,一期建成後年產能可達4萬公斤,使得公司具備在超材料尖端裝備領域的大規模、批量化的生產交付能力,可滿足客户對公司超材料尖端裝備產品未來3-5年的交付需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.